Teledyne Announces Third Quarter 2023 Earnings Webcast Details
Teledyne Technologies Incorporated (NYSE:TDY) will hold a conference call to discuss its third quarter 2023 results on Wednesday, October 25, 2023, at 8:00 a.m. Pacific. A press release with the third quarter financial results will be issued before the opening of the New York Stock Exchange on Wednesday, October 25, 2023.
To access the call, go to www.teledyne.com/investors/events-and-presentations approximately ten minutes before the scheduled start time. A replay will be available at this website for approximately one month starting at 9:00 a.m. Pacific on Wednesday, October 25, 2023.
Teledyne Technologies is a leading provider of sophisticated digital imaging products and software, instrumentation, aerospace and defense electronics, and engineered systems. Teledyne's operations are primarily located in the United States, Canada, the United Kingdom, and Western and Northern Europe. For more information, visit Teledyne's website at www.teledyne.com.
On June 29, the "Gather Great Wisdom to Shape the Future of Intelligent Manufacturing?Special Exhibition on Design Intelligence and High Quality Development", hosted by the China Academy of Art (CAA), opened at the National Museum of China in...
Intermap Technologies ("Intermap" or the "Company"), a global leader in 3D geospatial products and intelligence solutions, announces a new financing. The Company is offering up to a maximum of 4,300,000 Class "A" common shares of the Company...
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that on July 2, 2024, in relation to...
Enterprises in Asia Pacific are moving toward software-defined networking (SDN) to make communication more secure and resilient and speed up business decision-making, according to a new research report published today by Information Services Group...
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal...
